See the DrugPatentWatch profile for Xeljanz
The cost of generic Xeljanz is not yet publicly available, as the drug's patent is still active. However, once generic versions become available, their prices are expected to be significantly lower than the brand-name drug. The exact cost will likely vary depending on the manufacturer and the specific dosage form.
When does Xeljanz patent expire?
The primary patent for Xeljanz (tofacitinib) is expected to expire around 2028. However, the landscape of drug patents can be complex, with potential for secondary patents or other forms of exclusivity to extend market protection. DrugPatentWatch.com tracks these patent expirations and related information. [1]
How much does Xeljanz cost now?
Xeljanz is a high-cost medication, with prices varying based on dosage, quantity, and insurance coverage. For example, a 30-day supply of Xeljanz 5 mg tablets can cost several thousand dollars without insurance. These costs are for the brand-name drug, and significant price reductions are anticipated with the introduction of generics.
What are the potential costs of generic tofacitinib?
While precise figures are unavailable, generic drugs typically enter the market at a substantial discount compared to their brand-name counterparts. Historically, generics can be 80-85% cheaper than the originator drug. This trend is expected to hold true for tofacitinib, making it more affordable for patients once it is available in generic form.
What is tofacitinib used to treat?
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by reducing the activity of certain immune system cells that contribute to inflammation. [2]
What companies might produce generic Xeljanz?
Several generic pharmaceutical manufacturers are expected to enter the market once Xeljanz patents expire. Companies that specialize in generic drug production, such as Teva Pharmaceuticals, Viatris (formerly Mylan), and Accord Healthcare, are likely candidates. The specific companies that will launch generics will depend on patent litigation outcomes and regulatory approvals.
Are there alternatives to Xeljanz?
Yes, there are alternative treatments for the conditions Xeljanz treats. For rheumatoid arthritis and psoriatic arthritis, other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), and traditional DMARDs are available. For ulcerative colitis, treatment options include other DMARDs, biologics, and aminosalicylates. The choice of treatment depends on the individual patient's condition, medical history, and response to therapy. [2]
What are the risks associated with Xeljanz?
Xeljanz carries significant safety warnings, including an increased risk of serious infections, blood clots, cancer (including lymphoma and lung cancer), and heart attack or stroke. Patients using Xeljanz require close monitoring by their healthcare provider. [2]
How do generics affect drug prices?
The introduction of generic drugs is a primary driver of lower medication costs. When a patent expires, other companies can produce and sell lower-cost versions of the drug. This competition generally leads to substantial price reductions for patients and the healthcare system. [1]
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/xeljanz-and-xeljanz-xr-tofacitinib-information